Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial

Detalhes bibliográficos
Autor(a) principal: Melo, Fernanda S. Correia
Data de Publicação: 2018
Outros Autores: Leal, Gustavo Carneiro Gomes, Carvalho, Michelle S., Nunes, Ana Paula Jesus, Ferreira, Carolina B. N., Vieira, Flávia, Magnavita, Guilherme, Vale, Lucas A. S., Mello, Rodrigo P., Nakahira, Carolina, Argolo, Felipe C., Cardoso, Tanise, Souza, Cezar D. S., Fontes, Ana Teresa Caliman, Ferreira, Marcelo B., Freitas, Lucas Araújo de, Tuena, Marco A., Echegaray, Mariana V. F., Cavalcanti, Diogo E., Lucchese, Ana C., Bandeira, Igor Dorea, Telles, Manuela, Lima, Cássio S., Sampaio, Aline Santos, Silva, Samantha Siqueira, Marback, Roberta F., Del-Porto, José A., Abreu, José Neander, Sarin, Luciana M., Paixão, Camilla Sampaio, Carvalho, Lucas Pedreira de, Machado, Paulo Roberto Lima, Turecki, Gustavo, Lacerda, Acioly L. T., Quarantini, Lucas C.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/30736
Resumo: Carvalho, Lucas Pedreira de. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Pesquisa Clínica. Salvador, BA, Brasil. a Postgraduate Program in Medicine and Health, b Psychiatry Service, University Hospital, Universidade Federal da Bahia, Salvador, c LiNC—Laboratório Interdisciplinar de Neurociências Clínicas, d Depatment of Anesthesiology, e PRODAF—Programa de Transtornos Afetivos, Universidade Federal de São Paulo, São Paulo, f Postgraduate Program in Psychology, Institute of Psychology, g Immunology Service, Universidade Federal da Bahial, h Clinical Research Laboratory (LAPEC), Gonçalo Moniz Institute, Fiocruz-Bahia, Salvador, Brazil, i McGill Group for Suicide Studies, Douglas Mental Health University Institute & Department of Psychiatry, McGill University, Montreal, Canada, j Center for Research and Clinical Trials Sinapse-Bairral, Instituto Bairral de Psiquiatria, Itapira, Brazil.
id CRUZ_880ec30c0f5e5b582e8b101d0dec931b
oai_identifier_str oai:www.arca.fiocruz.br:icict/30736
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Melo, Fernanda S. CorreiaLeal, Gustavo Carneiro GomesCarvalho, Michelle S.Nunes, Ana Paula JesusFerreira, Carolina B. N.Vieira, FláviaMagnavita, GuilhermeVale, Lucas A. S.Mello, Rodrigo P.Nakahira, CarolinaArgolo, Felipe C.Cardoso, TaniseSouza, Cezar D. S.Fontes, Ana Teresa CalimanFerreira, Marcelo B.Freitas, Lucas Araújo deTuena, Marco A.Echegaray, Mariana V. F.Cavalcanti, Diogo E.Lucchese, Ana C.Bandeira, Igor DoreaTelles, ManuelaLima, Cássio S.Sampaio, Aline SantosSilva, Samantha SiqueiraMarback, Roberta F.Del-Porto, José A.Abreu, José NeanderSarin, Luciana M.Paixão, Camilla SampaioCarvalho, Lucas Pedreira deMachado, Paulo Roberto LimaTurecki, GustavoLacerda, Acioly L. T.Quarantini, Lucas C.2018-12-21T16:45:26Z2018-12-21T16:45:26Z2018MELO, Fernanda S. Correia et al. Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. Medicine, Baltimore, v. 97, n. 38, p. e12414, 2018.0025-7974https://www.arca.fiocruz.br/handle/icict/3073610.1097/MD.0000000000012414Carvalho, Lucas Pedreira de. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Pesquisa Clínica. Salvador, BA, Brasil. a Postgraduate Program in Medicine and Health, b Psychiatry Service, University Hospital, Universidade Federal da Bahia, Salvador, c LiNC—Laboratório Interdisciplinar de Neurociências Clínicas, d Depatment of Anesthesiology, e PRODAF—Programa de Transtornos Afetivos, Universidade Federal de São Paulo, São Paulo, f Postgraduate Program in Psychology, Institute of Psychology, g Immunology Service, Universidade Federal da Bahial, h Clinical Research Laboratory (LAPEC), Gonçalo Moniz Institute, Fiocruz-Bahia, Salvador, Brazil, i McGill Group for Suicide Studies, Douglas Mental Health University Institute & Department of Psychiatry, McGill University, Montreal, Canada, j Center for Research and Clinical Trials Sinapse-Bairral, Instituto Bairral de Psiquiatria, Itapira, Brazil.Allergan and Lundbeck and research fees from Janssen Pharmaceutical during the last 12 months. ALTL has received consulting fees from Janssen Pharmaceutical, Daiichi Sankyo Brasil, Cristalia Produtos Químicos e Farmacêuticos, Libbs Farmacêutica and SanofiAventis and has received research fees from Eli Lilly, H. Lundbeck A/S, Servier Laboratories, Hoffman-La Roche and Forum Pharmaceuticals during the last 12 months.Múltipla - ver em NotasThe use of ketamine as an option in the treatment of depressive disorder is growing rapidly, supported by numerous clinical trials attesting its efficacy and safety. Esketamine, the S (+) enantiomer of ketamine, is the most widely used form in the anesthetic environment in some countries, and new studies have shown that it may also be effective in depression and with better tolerability. However, no study so far has directly compared esketamine with racemic ketamine. Here we propose a protocol of a clinical trial to evaluate esketamine as a noninferior medicationMethods/design: This study protocol is for a randomized, controlled, double-blind noninferiority clinical trial. Subjects will be 18 years or older, with major depression characterized as treatment-resistant. Participants will receive a single infusion of either esketamine (0.25mg/kg) or ketamine (0.5 mg/kg) over 40 minutes. The primary outcome will be the difference in remission rates between the 2 treatment arms at 24 and 72hours after drug infusion. Secondary outcomes will include other timepoints, measurements of cognition, dissociation, and blood biomarkers. Discussion: A head-to-head study is the best way to evaluate whether the esketamine is in fact comparable to the racemic ketamine in terms of both efficacy and safety, and, if positive, it would be an initial step to increase the access to that type of treatment worldwide. Ethics and dissemination: The study was approved by the local Institutional Review Board (University Hospital Professor Edgard Santos—Federal University of Bahia—Number: 46657415.0.0000.0049). Subjects will only participate after voluntarily agreeing and signing the Informed Consent Form. The study findings will be published in peer-reviewed journals and presented at national and international conferences. Trial registration: This trial has been registered in the Japan Primary Registries Network (JPRN): UMIN000032355, which is affiliated with the World Health Organization. when compared to ketamine in the treatment of patients with treatment-resistant depression.engWillams & WilkinsEnsaio clínicoDepressãoEsketaminaIsomerismoCetaminaResistente ao tratamentoClinical trialDepressionEsketamineIsomerismKetamineTreatment resistantComparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trialinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZLICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/30736/1/license.txt5a560609d32a3863062d77ff32785d58MD51ORIGINALMelo FSC Comparative_study_of_esketamine_and_racemic.64.pdfMelo FSC Comparative_study_of_esketamine_and_racemic.64.pdfapplication/pdf212500https://www.arca.fiocruz.br/bitstream/icict/30736/2/Melo%20FSC%20Comparative_study_of_esketamine_and_racemic.64.pdf350198044d38100f8cc9dd703451de7cMD52TEXTMelo FSC Comparative_study_of_esketamine_and_racemic.64.pdf.txtMelo FSC Comparative_study_of_esketamine_and_racemic.64.pdf.txtExtracted texttext/plain34578https://www.arca.fiocruz.br/bitstream/icict/30736/3/Melo%20FSC%20Comparative_study_of_esketamine_and_racemic.64.pdf.txt1204b67d8b264b1cc9cf5472c4ab4c74MD53icict/307362023-03-15 14:34:16.299oai:www.arca.fiocruz.br:icict/30736Q0VTU8ODTyBOw4NPIEVYQ0xVU0lWQSBERSBESVJFSVRPUyBBVVRPUkFJUwoKQW8gYWNlaXRhciBvcyBURVJNT1MgZSBDT05EScOHw5VFUyBkZXN0YSBDRVNTw4NPLCBvIEFVVE9SIGUvb3UgVElUVUxBUiBkZSBkaXJlaXRvcwphdXRvcmFpcyBzb2JyZSBhIE9CUkEgZGUgcXVlIHRyYXRhIGVzdGUgZG9jdW1lbnRvOgoKKDEpIENFREUgZSBUUkFOU0ZFUkUsIHRvdGFsIGUgZ3JhdHVpdGFtZW50ZSwgw6AgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaLCBlbQpjYXLDoXRlciBwZXJtYW5lbnRlLCBpcnJldm9nw6F2ZWwgZSBOw4NPIEVYQ0xVU0lWTywgdG9kb3Mgb3MgZGlyZWl0b3MgcGF0cmltb25pYWlzIE7Dg08KQ09NRVJDSUFJUyBkZSB1dGlsaXphw6fDo28gZGEgT0JSQSBhcnTDrXN0aWNhIGUvb3UgY2llbnTDrWZpY2EgaW5kaWNhZGEgYWNpbWEsIGluY2x1c2l2ZSBvcyBkaXJlaXRvcwpkZSB2b3ogZSBpbWFnZW0gdmluY3VsYWRvcyDDoCBPQlJBLCBkdXJhbnRlIHRvZG8gbyBwcmF6byBkZSBkdXJhw6fDo28gZG9zIGRpcmVpdG9zIGF1dG9yYWlzLCBlbQpxdWFscXVlciBpZGlvbWEgZSBlbSB0b2RvcyBvcyBwYcOtc2VzOwoKKDIpIEFDRUlUQSBxdWUgYSBjZXNzw6NvIHRvdGFsIG7Do28gZXhjbHVzaXZhLCBwZXJtYW5lbnRlIGUgaXJyZXZvZ8OhdmVsIGRvcyBkaXJlaXRvcyBhdXRvcmFpcwpwYXRyaW1vbmlhaXMgbsOjbyBjb21lcmNpYWlzIGRlIHV0aWxpemHDp8OjbyBkZSBxdWUgdHJhdGEgZXN0ZSBkb2N1bWVudG8gaW5jbHVpLCBleGVtcGxpZmljYXRpdmFtZW50ZSwKb3MgZGlyZWl0b3MgZGUgZGlzcG9uaWJpbGl6YcOnw6NvIGUgY29tdW5pY2HDp8OjbyBww7pibGljYSBkYSBPQlJBLCBlbSBxdWFscXVlciBtZWlvIG91IHZlw61jdWxvLAppbmNsdXNpdmUgZW0gUmVwb3NpdMOzcmlvcyBEaWdpdGFpcywgYmVtIGNvbW8gb3MgZGlyZWl0b3MgZGUgcmVwcm9kdcOnw6NvLCBleGliacOnw6NvLCBleGVjdcOnw6NvLApkZWNsYW1hw6fDo28sIHJlY2l0YcOnw6NvLCBleHBvc2nDp8OjbywgYXJxdWl2YW1lbnRvLCBpbmNsdXPDo28gZW0gYmFuY28gZGUgZGFkb3MsIHByZXNlcnZhw6fDo28sIGRpZnVzw6NvLApkaXN0cmlidWnDp8OjbywgZGl2dWxnYcOnw6NvLCBlbXByw6lzdGltbywgdHJhZHXDp8OjbywgZHVibGFnZW0sIGxlZ2VuZGFnZW0sIGluY2x1c8OjbyBlbSBub3ZhcyBvYnJhcyBvdQpjb2xldMOibmVhcywgcmV1dGlsaXphw6fDo28sIGVkacOnw6NvLCBwcm9kdcOnw6NvIGRlIG1hdGVyaWFsIGRpZMOhdGljbyBlIGN1cnNvcyBvdSBxdWFscXVlciBmb3JtYSBkZQp1dGlsaXphw6fDo28gbsOjbyBjb21lcmNpYWw7CgooMykgUkVDT05IRUNFIHF1ZSBhIGNlc3PDo28gYXF1aSBlc3BlY2lmaWNhZGEgY29uY2VkZSDDoCBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPCkNSVVogbyBkaXJlaXRvIGRlIGF1dG9yaXphciBxdWFscXVlciBwZXNzb2Eg4oCTIGbDrXNpY2Egb3UganVyw61kaWNhLCBww7pibGljYSBvdSBwcml2YWRhLCBuYWNpb25hbCBvdQplc3RyYW5nZWlyYSDigJMgYSBhY2Vzc2FyIGUgdXRpbGl6YXIgYW1wbGFtZW50ZSBhIE9CUkEsIHNlbSBleGNsdXNpdmlkYWRlLCBwYXJhIHF1YWlzcXVlcgpmaW5hbGlkYWRlcyBuw6NvIGNvbWVyY2lhaXM7CgooNCkgREVDTEFSQSBxdWUgYSBvYnJhIMOpIGNyaWHDp8OjbyBvcmlnaW5hbCBlIHF1ZSDDqSBvIHRpdHVsYXIgZG9zIGRpcmVpdG9zIGFxdWkgY2VkaWRvcyBlIGF1dG9yaXphZG9zLApyZXNwb25zYWJpbGl6YW5kby1zZSBpbnRlZ3JhbG1lbnRlIHBlbG8gY29udGXDumRvIGUgb3V0cm9zIGVsZW1lbnRvcyBxdWUgZmF6ZW0gcGFydGUgZGEgT0JSQSwKaW5jbHVzaXZlIG9zIGRpcmVpdG9zIGRlIHZveiBlIGltYWdlbSB2aW5jdWxhZG9zIMOgIE9CUkEsIG9icmlnYW5kby1zZSBhIGluZGVuaXphciB0ZXJjZWlyb3MgcG9yCmRhbm9zLCBiZW0gY29tbyBpbmRlbml6YXIgZSByZXNzYXJjaXIgYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVogZGUKZXZlbnR1YWlzIGRlc3Blc2FzIHF1ZSB2aWVyZW0gYSBzdXBvcnRhciwgZW0gcmF6w6NvIGRlIHF1YWxxdWVyIG9mZW5zYSBhIGRpcmVpdG9zIGF1dG9yYWlzIG91CmRpcmVpdG9zIGRlIHZveiBvdSBpbWFnZW0sIHByaW5jaXBhbG1lbnRlIG5vIHF1ZSBkaXogcmVzcGVpdG8gYSBwbMOhZ2lvIGUgdmlvbGHDp8O1ZXMgZGUgZGlyZWl0b3M7CgooNSkgQUZJUk1BIHF1ZSBjb25oZWNlIGEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTwpPU1dBTERPIENSVVogZSBhcyBkaXJldHJpemVzIHBhcmEgbyBmdW5jaW9uYW1lbnRvIGRvIHJlcG9zaXTDs3JpbyBpbnN0aXR1Y2lvbmFsIEFSQ0EuCgpBIFBvbMOtdGljYSBJbnN0aXR1Y2lvbmFsIGRlIEFjZXNzbyBBYmVydG8gZGEgRklPQ1JVWiAtIEZVTkRBw4fDg08gT1NXQUxETyBDUlVaIHJlc2VydmEKZXhjbHVzaXZhbWVudGUgYW8gQVVUT1Igb3MgZGlyZWl0b3MgbW9yYWlzIGUgb3MgdXNvcyBjb21lcmNpYWlzIHNvYnJlIGFzIG9icmFzIGRlIHN1YSBhdXRvcmlhCmUvb3UgdGl0dWxhcmlkYWRlLCBzZW5kbyBvcyB0ZXJjZWlyb3MgdXN1w6FyaW9zIHJlc3BvbnPDoXZlaXMgcGVsYSBhdHJpYnVpw6fDo28gZGUgYXV0b3JpYSBlIG1hbnV0ZW7Dp8OjbwpkYSBpbnRlZ3JpZGFkZSBkYSBPQlJBIGVtIHF1YWxxdWVyIHV0aWxpemHDp8Ojby4KCkEgUG9sw610aWNhIEluc3RpdHVjaW9uYWwgZGUgQWNlc3NvIEFiZXJ0byBkYSBGSU9DUlVaIC0gRlVOREHDh8ODTyBPU1dBTERPIENSVVoKcmVzcGVpdGEgb3MgY29udHJhdG9zIGUgYWNvcmRvcyBwcmVleGlzdGVudGVzIGRvcyBBdXRvcmVzIGNvbSB0ZXJjZWlyb3MsIGNhYmVuZG8gYW9zIEF1dG9yZXMKaW5mb3JtYXIgw6AgSW5zdGl0dWnDp8OjbyBhcyBjb25kacOnw7VlcyBlIG91dHJhcyByZXN0cmnDp8O1ZXMgaW1wb3N0YXMgcG9yIGVzdGVzIGluc3RydW1lbnRvcy4KRepositório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-03-15T17:34:16Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
title Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
spellingShingle Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
Melo, Fernanda S. Correia
Ensaio clínico
Depressão
Esketamina
Isomerismo
Cetamina
Resistente ao tratamento
Clinical trial
Depression
Esketamine
Isomerism
Ketamine
Treatment resistant
title_short Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
title_full Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
title_fullStr Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
title_full_unstemmed Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
title_sort Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial
author Melo, Fernanda S. Correia
author_facet Melo, Fernanda S. Correia
Leal, Gustavo Carneiro Gomes
Carvalho, Michelle S.
Nunes, Ana Paula Jesus
Ferreira, Carolina B. N.
Vieira, Flávia
Magnavita, Guilherme
Vale, Lucas A. S.
Mello, Rodrigo P.
Nakahira, Carolina
Argolo, Felipe C.
Cardoso, Tanise
Souza, Cezar D. S.
Fontes, Ana Teresa Caliman
Ferreira, Marcelo B.
Freitas, Lucas Araújo de
Tuena, Marco A.
Echegaray, Mariana V. F.
Cavalcanti, Diogo E.
Lucchese, Ana C.
Bandeira, Igor Dorea
Telles, Manuela
Lima, Cássio S.
Sampaio, Aline Santos
Silva, Samantha Siqueira
Marback, Roberta F.
Del-Porto, José A.
Abreu, José Neander
Sarin, Luciana M.
Paixão, Camilla Sampaio
Carvalho, Lucas Pedreira de
Machado, Paulo Roberto Lima
Turecki, Gustavo
Lacerda, Acioly L. T.
Quarantini, Lucas C.
author_role author
author2 Leal, Gustavo Carneiro Gomes
Carvalho, Michelle S.
Nunes, Ana Paula Jesus
Ferreira, Carolina B. N.
Vieira, Flávia
Magnavita, Guilherme
Vale, Lucas A. S.
Mello, Rodrigo P.
Nakahira, Carolina
Argolo, Felipe C.
Cardoso, Tanise
Souza, Cezar D. S.
Fontes, Ana Teresa Caliman
Ferreira, Marcelo B.
Freitas, Lucas Araújo de
Tuena, Marco A.
Echegaray, Mariana V. F.
Cavalcanti, Diogo E.
Lucchese, Ana C.
Bandeira, Igor Dorea
Telles, Manuela
Lima, Cássio S.
Sampaio, Aline Santos
Silva, Samantha Siqueira
Marback, Roberta F.
Del-Porto, José A.
Abreu, José Neander
Sarin, Luciana M.
Paixão, Camilla Sampaio
Carvalho, Lucas Pedreira de
Machado, Paulo Roberto Lima
Turecki, Gustavo
Lacerda, Acioly L. T.
Quarantini, Lucas C.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Melo, Fernanda S. Correia
Leal, Gustavo Carneiro Gomes
Carvalho, Michelle S.
Nunes, Ana Paula Jesus
Ferreira, Carolina B. N.
Vieira, Flávia
Magnavita, Guilherme
Vale, Lucas A. S.
Mello, Rodrigo P.
Nakahira, Carolina
Argolo, Felipe C.
Cardoso, Tanise
Souza, Cezar D. S.
Fontes, Ana Teresa Caliman
Ferreira, Marcelo B.
Freitas, Lucas Araújo de
Tuena, Marco A.
Echegaray, Mariana V. F.
Cavalcanti, Diogo E.
Lucchese, Ana C.
Bandeira, Igor Dorea
Telles, Manuela
Lima, Cássio S.
Sampaio, Aline Santos
Silva, Samantha Siqueira
Marback, Roberta F.
Del-Porto, José A.
Abreu, José Neander
Sarin, Luciana M.
Paixão, Camilla Sampaio
Carvalho, Lucas Pedreira de
Machado, Paulo Roberto Lima
Turecki, Gustavo
Lacerda, Acioly L. T.
Quarantini, Lucas C.
dc.subject.other.pt_BR.fl_str_mv Ensaio clínico
Depressão
Esketamina
Isomerismo
Cetamina
Resistente ao tratamento
topic Ensaio clínico
Depressão
Esketamina
Isomerismo
Cetamina
Resistente ao tratamento
Clinical trial
Depression
Esketamine
Isomerism
Ketamine
Treatment resistant
dc.subject.en.pt_BR.fl_str_mv Clinical trial
Depression
Esketamine
Isomerism
Ketamine
Treatment resistant
description Carvalho, Lucas Pedreira de. Fundação Oswaldo Cruz. Instituto Gonçalo Moniz. Laboratório de Pesquisa Clínica. Salvador, BA, Brasil. a Postgraduate Program in Medicine and Health, b Psychiatry Service, University Hospital, Universidade Federal da Bahia, Salvador, c LiNC—Laboratório Interdisciplinar de Neurociências Clínicas, d Depatment of Anesthesiology, e PRODAF—Programa de Transtornos Afetivos, Universidade Federal de São Paulo, São Paulo, f Postgraduate Program in Psychology, Institute of Psychology, g Immunology Service, Universidade Federal da Bahial, h Clinical Research Laboratory (LAPEC), Gonçalo Moniz Institute, Fiocruz-Bahia, Salvador, Brazil, i McGill Group for Suicide Studies, Douglas Mental Health University Institute & Department of Psychiatry, McGill University, Montreal, Canada, j Center for Research and Clinical Trials Sinapse-Bairral, Instituto Bairral de Psiquiatria, Itapira, Brazil.
publishDate 2018
dc.date.accessioned.fl_str_mv 2018-12-21T16:45:26Z
dc.date.available.fl_str_mv 2018-12-21T16:45:26Z
dc.date.issued.fl_str_mv 2018
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv MELO, Fernanda S. Correia et al. Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. Medicine, Baltimore, v. 97, n. 38, p. e12414, 2018.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/30736
dc.identifier.issn.pt_BR.fl_str_mv 0025-7974
dc.identifier.doi.none.fl_str_mv 10.1097/MD.0000000000012414
identifier_str_mv MELO, Fernanda S. Correia et al. Comparative study of esketamine and racemic ketamine in treatment-resistant depression: Protocol for a non-inferiority clinical trial. Medicine, Baltimore, v. 97, n. 38, p. e12414, 2018.
0025-7974
10.1097/MD.0000000000012414
url https://www.arca.fiocruz.br/handle/icict/30736
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Willams & Wilkins
publisher.none.fl_str_mv Willams & Wilkins
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/30736/1/license.txt
https://www.arca.fiocruz.br/bitstream/icict/30736/2/Melo%20FSC%20Comparative_study_of_esketamine_and_racemic.64.pdf
https://www.arca.fiocruz.br/bitstream/icict/30736/3/Melo%20FSC%20Comparative_study_of_esketamine_and_racemic.64.pdf.txt
bitstream.checksum.fl_str_mv 5a560609d32a3863062d77ff32785d58
350198044d38100f8cc9dd703451de7c
1204b67d8b264b1cc9cf5472c4ab4c74
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1813009108623687680